keyword
MENU ▼
Read by QxMD icon Read
search

Infection acute myeloid leukaemia

keyword
https://www.readbyqxmd.com/read/28528711/clinical-impact-of-colonization-with-multidrug-resistant-organisms-on-outcome-after-autologous-stem-cell-transplantation-a-retrospective-single-center-study
#1
Sebastian Scheich, Claudia Reinheimer, Christian Brandt, Thomas A Wichelhaus, Michael Hogardt, Volkhard A J Kempf, Uta Brunnberg, Christian Brandts, Olivier Ballo, Ivana von Metzler, Johanna Kessel, Hubert Serve, Björn Steffen
During the last years, a significant increase in infections caused by multidrug-resistant organisms (MDRO) has been noticed, resulting in an increase of mortality in all fields of healthcare. Hematological patients are particularly affected by MDRO infections due to disease- and therapy-related immunosuppression. To determine the impact of colonization with MDRO on overall survival, we retrospectively analyzed data from patients undergoing autologous hematopoietic stem cell transplantation at our institution...
May 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28355465/clinical-considerations-in-the-early-treatment-of-invasive-mould-infections-and-disease
#2
Toine Mercier, Johan Maertens
Different therapeutic strategies for invasive fungal diseases have been explored, each with particular strengths and weaknesses. Broad-spectrum antifungal prophylaxis seems logical, but selective use is important due to its substantial disadvantages, including interference with diagnostic assays, selection for resistance, drug toxicity and drug-drug interactions. Antimould prophylaxis should be restricted to high-risk groups, such as patients undergoing intensive chemotherapy for acute myeloid leukaemia or myelodysplastic syndrome, allogeneic HSCT patients with prior invasive fungal infection, graft-versus-host-disease or extended neutropenia, recipients of a solid organ transplant, or patients with a high-risk inherited immunodeficiency...
March 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28324282/recurrent-bowel-blood-translocations-of-escherichia-coli-with-the-unique-virulence-characteristics-over-three-year-period-in-the-patient-with-acute-myeloid-leukaemia-case-report
#3
Beata Krawczyk, Anna Śledzińska, Agnieszka Piekarska, Andrzej Hellmann, Józef Kur
In patients with haematological malignancies, the bowel remains the main source of Escherichia coli bloodstream infections. We present the clinical example of recurrent bowel-blood translocations of E. coli with the unique virulence characteristics in a 55-year-old male with the diagnosis of acute myeloid leukaemia. The virulent factors profile of examined strains confirmed that the co-existence of genes papC, sfa, usp and cnf1, encoding virulence factors, predisposes E. coli to translocation from the gastrointestinal tract to the vascular bed...
March 21, 2017: Journal of Applied Genetics
https://www.readbyqxmd.com/read/28198173/delphi-based-study-and-analysis-of-key-risk-factors-for-invasive-fungal-infection-in-haematological-patients
#4
L Vázquez, M Salavert, J Gayoso, M Lizasoaín, I Ruiz Camps, N Di Benedetto
OBJECTIVE: Mortality caused by invasive fungal infections due to filamentous fungi (IFI-FF) is high. Predisposing factors to IFI-FF are multiple and should be stratified. The objective of this study was to identify key risk factors for IFI-FF in onco-haematological patients in different clinical settings. METHODS: Prospective national Delphi study. Risk factors for IFI-FF in patients with onco-haematological diseases were identified by a systematic review of the literature...
April 2017: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://www.readbyqxmd.com/read/28128441/restrictive-versus-liberal-red-blood-cell-transfusion-strategies-for-people-with-haematological-malignancies-treated-with-intensive-chemotherapy-or-radiotherapy-or-both-with-or-without-haematopoietic-stem-cell-support
#5
REVIEW
Lise J Estcourt, Reem Malouf, Marialena Trivella, Dean A Fergusson, Sally Hopewell, Michael F Murphy
BACKGROUND: Many people diagnosed with haematological malignancies experience anaemia, and red blood cell (RBC) transfusion plays an essential supportive role in their management. Different strategies have been developed for RBC transfusions. A restrictive transfusion strategy seeks to maintain a lower haemoglobin level (usually between 70 g/L to 90 g/L) with a trigger for transfusion when the haemoglobin drops below 70 g/L), whereas a liberal transfusion strategy aims to maintain a higher haemoglobin (usually between 100 g/L to 120 g/L, with a threshold for transfusion when haemoglobin drops below 100 g/L)...
January 27, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28109554/clinical-and-microbiological-characteristics-of-bloodstream-infections-among-patients-with-haematological-malignancies-with-and-without-neutropenia-at-a-medical-centre-in-northern-taiwan-2008-2013
#6
Chien-Yuan Chen, Feng-Ming Tien, Wang-Huei Sheng, Shang-Yi Huang, Ming Yao, Jih-Luh Tang, Woei Tsay, Hwei-Fang Tien, Po-Ren Hsueh
This study aimed to investigate the epidemiology and microbiology of bloodstream infections (BSIs) in patients with haematological malignancies. Clinical characteristics and microbiology of 2083 patients with haematological malignancy who were treated for BSI from 2008 to 2013 at a medical centre in Taiwan were retrospectively reviewed. Lymphoma (38.1%) was the most common, followed by acute myeloid leukaemia (30.9%). Of the 2090 non-duplicate BSI isolates, 1310 (62.7%) were recovered from patients with neutropenia...
March 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28019140/cutaneous-mucormycosis-as-result-of-insulin-administration-in-an-aml-patient-case-report-and-review-of-the-literature
#7
Anke Delie, Philip Vlummens, David Creytens, Eva Steel
We present a case of cutaneous mucormycosis in a patient with several important risk factors precipitating disease, namely underlying acute myeloid leukaemia and poorly controlled secondary diabetes. Inoculation was most likely caused by repeated minor trauma (insulin injection) at the site of infection. Treatment consisted of surgical debridement and liposomal Amphotericin B (LAmB) during 71 days. Posaconazole had already been initiated prior to infection as primary antifungal prophylaxis but was discontinued during follow-up as susceptibility testing later revealed resistance to posaconazole...
December 26, 2016: Acta Clinica Belgica
https://www.readbyqxmd.com/read/27891349/unusual-presentation-of-acute-leukaemia-a-tripod-of-cases
#8
Manjari Kishore, Vijay Kumar, Sadhna Marwah, Abhay S Nigam
Acute Leukemia is one of the common haematological malignancies encountered with varied clinical and haematological presentation. In acute leukaemia, complications like bleeding and infection cause significant morbidity and mortality, thus overshadowing the thromboembolic events. Among the various malignant haematological disorders, the association of thromboembolic events is often noted with acute promyelocytic leukemia, though the overall frequency of such events remains very low. Acute Lymphoblastic Leukemia (ALL) is, however, more common than Acute non-lymphoblastic Leukaemia...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27830376/clinical-effectiveness-of-itraconazole-as-antifungal-prophylaxis-in-aml-patients-undergoing-intensive-chemotherapy-in-the-modern-era
#9
C L Keighley, P Manii, S R Larsen, S van Hal
Antifungal prophylaxis regimens vary between centres, informed by local epidemiology and antifungal stewardship practices. The advantages of itraconazole over posaconazole prophylaxis include maintaining the utility of azole therapy for suspected breakthrough invasive fungal infection (bIFI). We examined the effectiveness and tolerability of itraconazole as prophylaxis in acute myeloid leukaemia (AML) patients. We sought to determine the rate of probable and proven bIFI in the context of itraconazole prophylaxis in a real-life setting...
February 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27790720/a-phase-2-trial-of-high-dose-lenalidomide-in-patients-with-relapsed-refractory-higher-risk-myelodysplastic-syndromes-and-acute-myeloid-leukaemia-with-trilineage-dysplasia
#10
Amer M Zeidan, B Douglas Smith, Hetty E Carraway, Ivana Gojo, Amy DeZern, Steven D Gore
Limited therapies exist for patients with refractory and relapsed (RR) higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukaemia with trilineage dysplasia (AML-TD). High dose (HD) lenalidomide (50 mg) has activity as frontline therapy in elderly AML but there is limited data in the RR setting. This phase II trial included patients with RR HR-MDS or AML-TD at 2 doses of lenalidomide (15 or 50 mg) on days 1-28 of 42-day cycles. The primary endpoint was response rate using the 2006 International Working Group criteria...
January 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/27667012/long-lasting-protective-effect-of-posaconazole-prophylaxis-in-patients-with-acute-myeloid-leukemia-receiving-allogeneic-hematopoietic-stem-cell-transplantation
#11
Alessandro Busca, Anna Candoni, Ernesta Audisio, Roberto Passera, Benedetto Bruno, Federico Monaco, Nicola Mordini, Adriana Vacca, Mario Delia, Franco Aversa, Livio Pagano
Patients with acute myeloid leukemia (AML) during induction chemotherapy and those who receive allogeneic hematopoietic stem cell transplantation (HSCT) are at higher risk of invasive fungal infections (IFI). In the present study, we investigated whether the risk of IFI in AML patients receiving HSCT might be affected by the antifungal prophylaxis with posaconazole administered during the induction/salvage chemotherapy treatment. Between August 2001 and April 2015, 130 patients with AML received itraconazole/fluconazole (group A) and 99 received posaconazole (group B) as antifungal prophylaxis after induction/salvage chemotherapy at 7 Italian centers and all patients received fluconazole as antifungal prophylaxis after HSCT...
December 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27374466/infusion-of-a-non-hla-matched-ex-vivo-expanded-cord-blood-progenitor-cell-product-after-intensive-acute-myeloid-leukaemia-chemotherapy-a-phase-1-trial
#12
Colleen Delaney, Filippo Milano, Laura Cicconi, Megan Othus, Pamela S Becker, Vicky Sandhu, Ian Nicoud, Ann Dahlberg, Irwin D Bernstein, Frederick R Appelbaum, Elihu H Estey
BACKGROUND: The intensive chemotherapy regimens used to treat acute myeloid leukaemia routinely result in serious infections, largely due to prolonged neutropenia. We investigated the use of non-HLA-matched ex-vivo expanded cord blood progenitor cells to accelerate haemopoietic recovery and reduce infections after chemotherapy. METHODS: We enrolled patients with a diagnosis of acute myeloid leukaemia by WHO criteria and aged 18-70 years inclusive at our institution (Fred Hutchinson Cancer Research Center) into this phase 1 trial...
July 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27346972/extreme-hyperferritinemia-in-the-setting-of-acute-myeloid-leukaemia-a-case-report-of-hemophagocytic-lymphohistiocytosis
#13
Damien Denimal, Louise Ménégaut, Cédric Rossi, Laurence Duvillard, David Masson
INTRODUCTION: Major hyperferritinemia is a rare feature in clinical laboratories associated with a wide variety of disorders, including hemophagocytic lymphohistiocytosis (HLH). The diagnosis of HLH is based on clinical and biological criteria, such as those proposed by the Histiocyte Society. However, several of these criteria are not relevant in the specific setting of hematologic malignancies. MATERIALS AND METHODS: A 69-year-old male was treated for an acute myeloid leukaemia...
2016: Biochemia Medica: časopis Hrvatskoga Društva Medicinskih Biokemičara
https://www.readbyqxmd.com/read/27264037/potentially-avoidable-hospital-admissions-in-older-patients-with-acute-myeloid-leukaemia-in-the-usa-a-retrospective-analysis
#14
Areej El-Jawahri, Tanya Keenan, Gregory A Abel, David P Steensma, Thomas W LeBlanc, Yi-Bin Chen, Gabriela Hobbs, Lara Traeger, Amir T Fathi, Daniel J DeAngelo, Martha Wadleigh, Karen K Ballen, Philip C Amrein, Richard M Stone, Jennifer S Temel
BACKGROUND: Older adults (≥60 years of age) with acute myeloid leukaemia spend a substantial proportion of their life in hospital after diagnosis. We examined reasons for their hospital admissions and identified potentially avoidable hospital admissions (PAH) in this age group in the USA. METHODS: In this retrospective analysis, we examined the reasons for hospital admissions in older patients diagnosed with and treated for acute myeloid leukaemia at two tertiary care hospitals in the USA...
June 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27161689/po-02-retrospective-audit-of-the-peripherally-inserted-central-catheter-picc-associated-thrombosis-in-patients-with-haematological-malignancies-at-cork-university-hospital
#15
E McAuliffe, S O'Shea, M I Khan
INTRODUCTION: Peripherally inserted central catheters (PICC) have been increasingly used for administration of chemotherapy, antibiotics and blood products in patients with haematological malignancies. Although generally regarded safe, infections and thrombotic events have occurred with PICC use, necessitating study to guide future clinical prophylaxis and management. AIM: 1) Determine the incidence of PICC associated thrombosis in patients with haematological malignancies 2) To identify clinically significant risk factors contributing to these complications...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27061932/a-cluster-of-geotrichum-clavatum-saprochaete-clavata-infection-in-haematological-patients-a-first-italian-report-and-review-of-literature
#16
REVIEW
Maria Ilaria Del Principe, Loredana Sarmati, Mariagiovanna Cefalo, Carla Fontana, Giovanna De Santis, Francesco Buccisano, Luca Maurillo, Eleonora De Bellis, Massimiliano Postorino, Giuseppe Sconocchia, Giovanni Del Poeta, Maurizio Sanguinetti, Sergio Amadori, Livio Pagano, Adriano Venditti
Invasive fungal infections, usually Aspergillus and Candida, represent a major cause of morbidity and mortality in patients with malignant haematological diseases, but in the last years rare fungal infections have more frequently been reported. Here, we report the clinical history of three patients affected with haematological malignancies who developed an infection caused by Geotrichum (G.) clavatum. Two out of three patients were affected by acute myeloid leukaemia (AML), and one by mantle cell lymphoma (MCL)...
September 2016: Mycoses
https://www.readbyqxmd.com/read/27027972/invasive-fungal-infections-in-aml-mds-patients-treated-with-azacitidine-a-risk-worth-considering-antifungal-prophylaxis
#17
Helena Pomares, Montserrat Arnan, Isabel Sánchez-Ortega, Anna Sureda, Rafael F Duarte
The aim of this study is to analyse the risk of invasive fungal infection (IFI) and the need for antifungal prophylaxis in patients with acute myeloid leukaemia and myelodysplastic syndromes (AML/MDS) treated with azacitidine. We retrospectively analysed the incidence of IFI according to EORTC-MSG criteria in 121 consecutive AML/MDS patients receiving 948 azacitidine courses (median 5, range 1-43) between June 2007 and June 2015. Four cases of IFI (two possible, one probable aspergillosis and one proven candidemia) occurred in this series...
August 2016: Mycoses
https://www.readbyqxmd.com/read/26967515/a-systematic-evaluation-of-the-safety-and-toxicity-of-fingolimod-for-its-potential-use-in-the-treatment-of-acute-myeloid-leukaemia
#18
Anoop K Enjeti, Angel D'Crus, Kathleen Melville, Nicole M Verrills, Philip Rowlings
Treatment of acute myeloid leukaemia (AML) is challenging and emerging treatment options include protein phosphatase 2A (PP2A) activators. Fingolimod is a known PP2A activator that inhibits multiple signalling pathways and has been used extensively in patients with multiple sclerosis and other indications. The initial positive results of PP2A activators in vitro and mouse models of AML are promising; however, its safety for use in AML has not been assessed. From human studies of fingolimod in other indications, it is possible to evaluate whether the safety and toxicity profile of the PP2A activators will allow their use in treating AML...
July 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/26954719/predicting-microbiologically-defined-infection-in-febrile-neutropenic-episodes-in-children-global-individual-participant-data-multivariable-meta-analysis
#19
Robert S Phillips, Lillian Sung, Roland A Amman, Richard D Riley, Elio Castagnola, Gabrielle M Haeusler, Robert Klaassen, Wim J E Tissing, Thomas Lehrnbecher, Julia Chisholm, Hana Hakim, Neil Ranasinghe, Marianne Paesmans, Ian M Hann, Lesley A Stewart
BACKGROUND: Risk-stratified management of fever with neutropenia (FN), allows intensive management of high-risk cases and early discharge of low-risk cases. No single, internationally validated, prediction model of the risk of adverse outcomes exists for children and young people. An individual patient data (IPD) meta-analysis was undertaken to devise one. METHODS: The 'Predicting Infectious Complications in Children with Cancer' (PICNICC) collaboration was formed by parent representatives, international clinical and methodological experts...
March 15, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/26880256/granulocyte-and-granulocyte-macrophage-colony-stimulating-factors-for-newly-diagnosed-patients-with-myelodysplastic-syndromes
#20
REVIEW
Franz Hutzschenreuter, Ina Monsef, Karl-Anton Kreuzer, Andreas Engert, Nicole Skoetz
BACKGROUND: Myelodysplastic syndromes (MDS) are a heterogeneous group of haematological diseases which are characterised by a uni- or multilineage dysplasia of haematological stem cells. Standard treatment is supportive care of the arising symptoms including red blood cell transfusions or the administration of erythropoiesis-stimulating agents (ESAs) in the case of anaemia or the treatment with granulocyte (G-CSF) and granulocyte-macrophage colony stimulating factors (GM-CSF) in cases of neutropenia...
February 16, 2016: Cochrane Database of Systematic Reviews
keyword
keyword
22643
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"